Figitumumab

Summary

Figitumumab (CHEMBL1743019) is a phase-3 clinical-stage antibody; indicated across 15 conditions including squamous cell carcinoma and lung large cell carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 15 conditions
• Clinical trials: 20

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743019
Name	Figitumumab
Type	Antibody
Max phase	3

Also known as: CP-751, CP-751,871, CP-751871, Figitumumab, FIGITUMUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

15 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
squamous cell carcinoma	3	MONDO:0005096	EFO:0000707
lung large cell carcinoma	3	MONDO:0003050	EFO:0003050
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
prostate adenocarcinoma	2	MONDO:0005082	EFO:0000673
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
breast neoplasm	2	MONDO:0021100	EFO:0003869
colorectal neoplasm	2	MONDO:0005335	EFO:0004142
head and neck cancer	2	MONDO:0005627	EFO:0006859
Ewing sarcoma	1	MONDO:0012817	EFO:0000174
sarcoma	1	MONDO:0005089	EFO:0000691
plasma cell myeloma	1	MONDO:0009693	EFO:0001378
lung neoplasm	1	MONDO:0021117	MONDO:0021117
neoplasm	1	MONDO:0005070	MONDO:0004992

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 20.

Phase distribution

Phase	Trials
PHASE1	10
PHASE2	6
PHASE3	2
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00596830	PHASE3	TERMINATED	Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
NCT00907504	PHASE3	WITHDRAWN	Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer
NCT00147537	PHASE1/PHASE2	COMPLETED	Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
NCT00313781	PHASE2	COMPLETED	Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)
NCT00372996	PHASE2	TERMINATED	Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
NCT00560235	PHASE1/PHASE2	COMPLETED	Study Of CP-751,871 In Patients With Ewing’s Sarcoma Family Of Tumors
NCT00560560	PHASE2	COMPLETED	Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments
NCT00678626	PHASE2	WITHDRAWN	Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer
NCT00872404	PHASE2	TERMINATED	A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma
NCT00977561	PHASE2	TERMINATED	A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer
NCT00474760	PHASE1	COMPLETED	Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors
NCT00560573	PHASE1	COMPLETED	Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer
NCT00603538	PHASE1	COMPLETED	Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung Cancer
NCT00635245	PHASE1	WITHDRAWN	CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery
NCT00729833	PHASE1	TERMINATED	Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors
NCT00926263	PHASE1	TERMINATED	A Pharmacokinetic And QT Study Of CP-751,871 In Healthy Subjects
NCT00927966	PHASE1	COMPLETED	RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms
NCT00976508	PHASE1	TERMINATED	Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
NCT01536145	PHASE1	COMPLETED	CP-751,871 Treatment For Patients With Multiple Myeloma
NCT01653158	PHASE1	COMPLETED	CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).